0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Calcitonin Therapy for Bone Disease and Hypercalcemia

Louis V. Avioli, MD
Arch Intern Med. 1982;142(12):2076-2079. doi:10.1001/archinte.1982.00340250034005.
Text Size: A A A
Published online

Since a "hypocalcemic substance" (ie, calcitonin) was first demonstrated in extracts of rat thyroid tissue by Hirsch et al1 in 1963, its role in maintaining mineral homeostasis has undergone extensive analyses. Mechanisms that regulate the secretion and the biological activity of calcitonin in healthy humans, patients with medullary carcinoma, and in lower animal species have been defined, and the sequence for the 32—amino acid calcitonin peptide isolated from human, bovine, ovine, salmon, and porcine thyroid glands established.2,3 Despite these many observations, which stem primarily from a combination of in vitro experiments on thyroid or ultimobranchial tissue, in situ perfusions of the thyroid gland of pigs, goats, cows, and dogs, and in vivo studies in rats following a multitude of dietary pertubations,2,4 the functional role of calcitonin in either conditioning or regulation mineral and skeletal metabolism in healthy humans is still conjectural at best. Women have lower basal

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();